cetuximab + irinotecan + mitomycin C

Cetuximab + irinotecan + mitomycin C is an investigational combination regimen composed of three distinct anticancer agents, each with a different mechanism of action. Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in tumor cell proliferation and survival. Irinotecan is a small molecule topoisomerase I inhibitor that induces DNA damage and apoptosis in rapidly dividing cells. Mitomycin C is an alkylating agent that crosslinks DNA, leading to inhibition of DNA synthesis and cell death. This combination has been studied primarily for the treatment of advanced or refractory colorectal cancer, particularly in patients who have failed prior standard therapies[2][1]. The rationale for combining these agents lies in their complementary mechanisms and potential synergistic antitumor effects.